A Phase 2/3 interventional study of Rabeprazole and Rabeprazole in Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin, sponsored by Eisai Co., Ltd.. Completed at 50 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-12-21.
Sponsored by Eisai Co., Ltd. · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Stomach Ulcer with a site in Japan — none open to participants now, none under way, none of them phase 3. Stomach Ulcer · Japan.
Among the 29 studies in Stomach Ulcer with a site in Japan, this one is the 10th largest by enrollment of the 20 interventional ones that give a count, is one of 8 that started in 2011, is one of 3 in phase 2/3, and was the 12th registered.
116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
Browse Stomach Ulcer studies →None of the 29 studies in Stomach Ulcer with a site in Japan is open now. The open studies under Stomach Ulcer, anywhere →
Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 18 · Phase 4 2
First in 2000; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 405 is above the median of 298 across 88 interventional studies indexed under Stomach Ulcer.
Median enrollment 400 across the 20 interventional studies, 1,999 across the 6 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 29 have an industry lead sponsor. The 5 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Eisai Co., Ltd. has 6 studies filed under Stomach Ulcer — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Stomach Ulcer with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study to examine the long-term safety of rabeprazole 5 mg or 10 mg tablets administered once daily in participants who were confirmed to have no recurrence of gastric or duodenal ulcer by endoscopic examination at the end of 24 weeks of treatment in the E3810-J081-308 (NCI01397448) [Double-Blind Phase] study. From a total of 420 participants who completed the E3810-J081-308 study, 328 entered the E3810-J081-309 (NCT01398410) study.
The E3810-J081-309 consisted of two arms: the long-term rabeprazole groups (participants from the rabeprazole 5 or 10 mg arm of the E3810-J081-308 study who entered the rabeprazole 5 mg or 10 mg arm of the E3810-J081-309 study) and the newly-initiated rabeprazole groups (participants from the teprenone 150 mg arm of the E3810-J081-308 study who entered the rabeprazole 5 mg or 10 mg arm of the E3810-J081-309 study).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
-Confirmed to have a recurrence of gastric or duodenal ulcer at the end of 24 weeks of treatment in study E3810-J081-308 (at the start of this trial) and thus are withdrawn from the trial.
Drug: Rabeprazole
Drug: Rabeprazole
Participants received rabeprazole 5 mg tablets and rabeprazole 10 mg matched placebo tablets orally, once daily
Also known as: E3810, Pariet/Aciphex
Participants received rabeprazole 10 mg tablets and rabeprazole 5 mg matched placebo tablets orally, once daily
Also known as: E3810, Pariet/Aciphex
Percentage of Participants With Treatment Emergent Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant administered with the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening (ie, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was as a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug). In this study, treatment emergent AEs (defined as an AE (serious/non-serious) that started/increased in severity on/after the first dose of study drug up to 30 days after the final dose of study drug) were assessed. The data is presented as percentage of participants with treatment emergent AEs.
Time frame: For each participant, from administration of first dose of study drug (rabeprazole) up to 30 days from administration of last dose of study drug (rabeprazole) or up to 76 weeks (including data from the Double-Blind Phase)
Cumulative Recurrent Rate of Gastric or Duodenal Ulcers
Mucosal injuries with a white coat measuring greater than or equal to 3 mm in diameter was diagnosed as ulcers. When ulcer was confirmed by endoscopic examination during the trial, it was regarded as recurrence of ulcer and the trial was discontinued for the participant involved. The presence or absence of ulcer recurrence was determined by the endoscopy central review panel that were blinded to the investigators' assessments. Cumulative recurrent rate was estimated by the Kaplan-Meier method. The data is presented as percentage of participants with cumulative recurrent rate of gastric or duodenal ulcers.
Time frame: Baseline, Week 12, Week 24, Week 52, and Week 76 (including data from the Double-Blind Phase)
| Milestone | Rabeprazole 5 mg | Rabeprazole 10 mg |
|---|---|---|
| Started | 201 | 204 |
| Completed | 143 | 148 |
| Not completed | 58 | 56 |
| Withdrew: Adverse event | 12 | 16 |
| Withdrew: Participants choice | 8 | 11 |
| Withdrew: Inadequate therapeutic effect | 2 | 0 |
| Withdrew: Other | 36 | 29 |
An AE was defined as any untoward medical occurrence in a participant administered with the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening (ie, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was as a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug). In this study, treatment emergent AEs (defined as an AE (serious/non-serious) that started/increased in severity on/after the first dose of study drug up to 30 days after the final dose of study drug) were assessed. The data is presented as percentage of participants with treatment emergent AEs.
| Percentage of participants | Rabeprazole 5 mg | Rabeprazole 10 mg |
|---|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events (AEs) | 77.1 | 83.8 |
Mucosal injuries with a white coat measuring greater than or equal to 3 mm in diameter was diagnosed as ulcers. When ulcer was confirmed by endoscopic examination during the trial, it was regarded as recurrence of ulcer and the trial was discontinued for the participant involved. The presence or absence of ulcer recurrence was determined by the endoscopy central review panel that were blinded to the investigators' assessments. Cumulative recurrent rate was estimated by the Kaplan-Meier method. The data is presented as percentage of participants with cumulative recurrent rate of gastric or duodenal ulcers.
| Percentage of participants | Rabeprazole 5 mg | Rabeprazole 10 mg |
|---|---|---|
| Baseline (N=150, 151) | 0 (0 to 0) | 0 (0 to 0) |
| Week 12 (N=150, 151) | 1.3 (0.34 to 5.23) | 0 (0 to 0) |
| Week 24 (N=139, 142) | 2.8 (1.04 to 7.17) | 1.4 (0.35 to 5.51) |
| Week 52 (N=107, 121) | 3.7 (1.53 to 8.64) | 2.2 (0.72 to 6.75) |
| Week 76 (N=93, 96) | 3.7 (1.53 to 8.64) | 2.2 (0.72 to 6.75) |
Collected over For each participant, from administration of first dose of study drug (rabeprazole) up to 30 days from administration of last dose of study drug or up to 76 weeks (including data from the Double-Blind Phase). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rabeprazole 5 mg | — | 33/201 (16.4%) | 89/201 (44.3%) |
| Rabeprazole10 mg | — | 30/204 (14.7%) | 99/204 (48.5%) |
| Event | Rabeprazole 5 mg | Rabeprazole10 mg |
|---|---|---|
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/201 | 4/204 |
| Angina pectorisCardiac disorders | 3/201 | 1/204 |
| CataractEye disorders | 2/201 | 1/204 |
| Coronary artery restenosisInjury, poisoning and procedural complications | 2/201 | 0/204 |
| Acute myocardial infarctionCardiac disorders | 1/201 | 0/204 |
| Cardiac failure chronicCardiac disorders | 1/201 | 0/204 |
| Mitral valve incompetenceCardiac disorders | 1/201 | 0/204 |
| Tricuspid valve incompetenceCardiac disorders | 1/201 | 0/204 |
| Vertigo positionalEar and labyrinth disorders | 1/201 | 0/204 |
| Diverticulum intestinal haemorrhagicGastrointestinal disorders | 1/201 | 0/204 |
| Event | Rabeprazole 5 mg | Rabeprazole10 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 64/201 | 57/204 |
| DiarrhoeaGastrointestinal disorders | 11/201 | 16/204 |
| ConstipationGastrointestinal disorders | 9/201 | 16/204 |
| Back painMusculoskeletal and connective tissue disorders | 14/201 | 13/204 |
| ContusionInjury, poisoning and procedural complications | 13/201 | 7/204 |
| EczemaSkin and subcutaneous tissue disorders | 6/201 | 12/204 |
| Age, Continuous(Years) | Rabeprazole 5 mg | Rabeprazole 10 mg | Total |
|---|---|---|---|
| Mean | 69.4 ± 8.5 | 70.1 ± 9.3 | 69.8 ± 8.9 |
| Sex: Female, Male(Participants) | Rabeprazole 5 mg | Rabeprazole 10 mg | Total |
|---|---|---|---|
| Female | 48 | 52 | 100 |
| Male | 153 | 152 | 305 |
The record gives a start of Dec 2011, a primary completion of Dec 2013 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole